Home » Stocks » NEXI

NexImmune, Inc. (NEXI)

Stock Price: $18.69 USD -1.31 (-6.55%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 420.93M
Revenue (ttm) n/a
Net Income (ttm) -26.98M
Shares Out 21.52M
EPS (ttm) -1.25
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $18.69
Previous Close $20.00
Change ($) -1.31
Change (%) -6.55%
Day's Open 20.45
Day's Range 18.03 - 21.04
Day's Volume 456,107
52-Week Range 17.06 - 28.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrat...

Benzinga - 2 weeks ago

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented t...

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, ONCR, PRTA, TLIS
GlobeNewsWire - 2 weeks ago

GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the ...

GlobeNewswire - 3 weeks ago

NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy...

NASDAQ - 1 month ago

NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering.

SEC - 1 month ago

NexImmune, Inc. has filed to go public with an IPO on the NASDAQ.

About NEXI

NexImmune, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.

Industry
Biotechnology
IPO Date
Feb 12, 2021
CEO
Scott Carmer
Employees
44
Stock Exchange
NASDAQ
Ticker Symbol
NEXI
Full Company Profile

Financial Performance

Financial Statements